Previous 10 | Next 10 |
home / stock / bcli / bcli articles
NEW YORK, Dec. 25, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Br...
NEW YORK, Dec. 19, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Br...
If you suffered losses exceeding $25,000 investing in Brainstorm securities between August 15, 2022 and September 27, 2023 and would like to discu...
If you suffered losses exceeding $25,000 investing in Brainstorm securities between August 15, 2022 and September 27, 2023 and would like to discu...
NEW YORK, Dec. 11, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Br...
Brainstorm Cell Therapeutics Inc (NASDAQ: BCLI) shares are trading lower by 22.6% to $0.23 Thursday afternoon after the company said it conclu...
If you suffered losses exceeding $25,000 investing in Brainstorm securities between August 15, 2022 and September 27, 2023 and would like to discu...
NEW YORK, Dec. 05, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Br...
If you suffered losses exceeding $25,000 investing in Brainstorm securities between August 15, 2022 and September 27, 2023 and would like to discu...
News, Short Squeeze, Breakout and More Instantly...
Brainstorm Cell Therapeutics Inc. Company Name:
BCLI Stock Symbol:
NASDAQ Market:
Brainstorm Cell Therapeutics Inc. Website:
BrainStorm Cell Therapeutics to Provide Corporate Mid-Year Update on NurOwn Program PR Newswire A conference call and webcast will be held Monday, July 8 , at 8:00 a.m. Eastern Time NEW YORK , July 1, 2024 /PRNewswire/ -- BrainStorm Cell Therapeut...
BrainStorm Cell Therapeutics Announces Pricing of $4.0 Million Registered Direct Offering PR Newswire NEW YORK , June 27, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) (the "Company"), a leading developer of adult stem cell therapeutics fo...
BrainStorm Cell Therapeutics Reaches Alignment with FDA on CMC Aspects of Phase 3b NurOwn® Clinical Trial PR Newswire NEW YORK , June 26, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell thera...